Design Therapeutics (DSGN) Financials

Design Therapeutics (NASDAQ: DSGN) remains a pre-revenue biotech with no product sales, so the company’s financial story is still centered on cash burn, investment income, and balance-sheet strength rather than operating growth. For Q1 2026, the company reported a net loss of $17.6 million, which was slightly worse than the $16.0 million loss in Q4 2025 and modestly larger than the $17.0 million loss in Q3 2025.

Revenue remains at zero, and operating expenses continue to drive losses. In Q1 2026, R&D expense was $14.4 million and SG&A expense was $5.3 million, bringing total operating expenses to $19.7 million. That’s up from $18.2 million in the prior quarter, showing that spending is still elevated.

One bright spot is the balance sheet. As of March 31, 2026, DSGN held $12.8 million in cash and $210.1 million in short-term investments, for total current assets of $227.0 million. Against that, total liabilities were only $12.4 million, leaving the company with a very strong liquidity position.

Cash flow was negative from operations in Q1 2026, with operating cash outflow of $16.4 million. However, the company partially offset this through financing, including $19.9 million from common equity issuance. Investing activities were also negative in the quarter, with a $7.6 million outflow after purchases and sales of investments.

Looking at the last four years of quarterly trends, DSGN has consistently posted no revenue, recurring net losses, and negative operating cash flow. The losses have generally ranged in the low-to-high teens millions per quarter, while the company has relied on its cash and marketable securities to fund research programs.

Overall, the company looks financially stable for now because of its large cash/investment reserve, but the core operating trend remains negative. Investors should focus on the pace of cash burn, future financing needs, and whether R&D spending is translating into meaningful clinical progress.

• Large liquidity cushion: Q1 2026 total current assets were $227.0 million, with $210.1 million in short-term investments and $12.8 million in cash.
• Very low leverage: total liabilities were just $12.4 million versus $218.1 million in equity.
• Investment income helps offset losses: Q1 2026 interest and investment income was $2.1 million.
• Equity financing support: the company raised $19.9 million from common equity issuance in Q1 2026.
• No revenue yet: DSGN continues to operate as a pre-commercial biotech with zero quarterly revenue.
• Ongoing R&D investment: research and development spending remains the largest operating expense, at $14.4 million in Q1 2026.
• Quarterly losses remain in line with prior periods: the Q1 2026 net loss of $17.6 million was similar to recent quarters.
• Negative operating cash flow: operations used $16.4 million in cash in Q1 2026.
• Higher operating costs quarter over quarter: total operating expenses rose from $18.2 million in Q4 2025 to $19.7 million in Q1 2026.
• Persistent shareholder dilution risk: the company has repeatedly funded operations through equity issuance over the past year.

In short, Design Therapeutics has the balance sheet strength to continue funding its pipeline, but it is still a cash-burning biotech with no product revenue and no clear sign yet of operating self-sufficiency.